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Transcranial sonography (TCS) has been recently recognized as a reliable and sensitive tool in detecting basal ganglia (BG) abnormalities in several movement disorders, where different patterned hyperechogenic lesions were demonstrated. The aim of this study was to investigate changes in TCS in a larger group of clinically stable patients with Wilson's disease (WD), and to correlate them with demographic and clinical data. TCS was conducted in 54 consecutive, clinically stable patients with WD who were classified as predominantly neurologic or hepatic form of the disease and were adequately assessable by TCS from both sides. TCS revealed significantly higher prevalence of SN (p = 0.007) and LN hyperechogenicity (0.001) in WD patients when compared to controls. Moderate to marked SN hyperechogenicity was found in 31.5% of WD patients (in 42% and 7% of those with neurologic and hepatic form of WD, respectively) and in 8% of healthy controls. Disease severity correlated with the hyperechogenicity of SN (r = 0.303; p = 0.029) and with the width of the third ventricle (r = 0.351; p = 0.011). There is only one report of TCS in WD previous to our study. Both studies proved the ability of TCS to detect accumulation of copper and probably other trace metals, such as iron and manganese, in the BG of WD patients.
This publication arises from the project « APHP FY_2012 » which has received funding from the European Union in the framework of the Health Programme We calculate that TCS is able to detect accumulation of copper and probably other trace metals, such as iron and manganese, in the BG of WD patients.
TCS revealed significantly higher prevalence of SN and LN hyperechogenicity in WD patients when compared to controls. Disease severity correlated with the hyperechogenicity of SN and with the width of the third ventricle.
Summary
Comments
Take home message
This publication arises from the project « APHP FY_2012 » which has received funding from the European Union in the framework of the Health Programme Wilson's disease (WD) is an autosomal recessive disease caused by mutations in the ATP7B gene, resulting in accumulation of copper in various organs including liver, cornea, and brain. AADSL and EASL Guidelines have been published to help physicians in diagnosis and treatment. We report diagnosis of WD in a 43-year-old asymptomatic father after his daughter had presented with a typical hepatic WD, and want to focus on recommendations about familial screening. The daughter (patient 1) was a previously healthy 10-year-old girl, who presented with hepatosplenomegaly. Additional testing confirmed the diagnosis of WD. Her parents were screened, although they were totally asymptomatic. The results obtained for the father (patient 2) were compatible with WD. By whole-gene sequencing, he was identified as a compound heterozygote and was treated with Zinc salts. In case of WD, it is highly recommended to perform familial screening . Both Guidelines recommend screening firstdegree relatives of the index case, suggesting siblings or children only. We usually know that WD occurs in siblings (25%) and the offspring (0.5%), but the risk also exists for the previous generation (0.5%), even if rarely reported. Moreover, WD disease occurs with different clinical presentations: hepatic, neurological, psychiatric disorder or asymptomatic. The phenotype of WD varies considerably among patients with the same genotype without any correlations, even within a single family. WD usually occurs between 3 and 40 years of age, but a later onset is possible. Considering the possibility of late onset, absence of symptoms, and absence of phenotype-genotype correlation in WD, it seems necessary to screen the previous generation, especially the parents of a new patient, as illustrated in our case report. The modalities of familial screening are important too. In our family, standard genetic testing for parents (search only for the two index case's mutations) would not have been sufficient to diagnose WD in patient 2. In conclusion, genetic counselling is essential for families of WD patients. Not only siblings and the offspring but also the previous generation of the index case must be screened by performing liver tests, explorations of copper metabolism, and suitable genetic testing.
Familial screening must include explorations of copper metabolism.
Familial screening in Wilson Disease is essential not only for siblings and offspring but also for previous generation.
